Loading...

Ergomed plc

2EM.DEXETRA
Healthcare
Biotechnology
11.00
0.00(0.00%)

Ergomed plc (2EM.DE) Company Profile & Overview

Explore Ergomed plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Ergomed plc (2EM.DE) Company Profile & Overview

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

SectorHealthcare
IndustryBiotechnology
CEOMiroslav Reljanovic

Contact Information

44 1483 503 205
Surrey Research Park, Guildford, GU2 7HJ

Company Facts

1,400 Employees
IPO DateAug 26, 2015
CountryGB

Frequently Asked Questions

;